收费全文 | 2366篇 |
免费 | 208篇 |
国内免费 | 7篇 |
耳鼻咽喉 | 16篇 |
儿科学 | 70篇 |
妇产科学 | 16篇 |
基础医学 | 307篇 |
口腔科学 | 53篇 |
临床医学 | 235篇 |
内科学 | 572篇 |
皮肤病学 | 23篇 |
神经病学 | 195篇 |
特种医学 | 82篇 |
外科学 | 280篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 160篇 |
眼科学 | 93篇 |
药学 | 245篇 |
肿瘤学 | 225篇 |
2023年 | 29篇 |
2022年 | 42篇 |
2021年 | 85篇 |
2020年 | 69篇 |
2019年 | 80篇 |
2018年 | 87篇 |
2017年 | 73篇 |
2016年 | 94篇 |
2015年 | 92篇 |
2014年 | 128篇 |
2013年 | 155篇 |
2012年 | 213篇 |
2011年 | 195篇 |
2010年 | 87篇 |
2009年 | 88篇 |
2008年 | 149篇 |
2007年 | 126篇 |
2006年 | 125篇 |
2005年 | 111篇 |
2004年 | 99篇 |
2003年 | 84篇 |
2002年 | 78篇 |
2001年 | 27篇 |
2000年 | 20篇 |
1999年 | 21篇 |
1998年 | 26篇 |
1997年 | 23篇 |
1996年 | 14篇 |
1995年 | 7篇 |
1994年 | 14篇 |
1993年 | 8篇 |
1991年 | 6篇 |
1990年 | 11篇 |
1989年 | 5篇 |
1987年 | 8篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 6篇 |
1974年 | 6篇 |
1971年 | 10篇 |
1970年 | 5篇 |
1968年 | 5篇 |
1967年 | 4篇 |
1965年 | 4篇 |
Aims/hypothesis
The double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) assessed the cardiovascular safety of insulin degludec. The incidence and rates of adjudicated severe hypoglycaemia, and all-cause mortality were also determined. This paper reports a secondary analysis investigating associations of severe hypoglycaemia with cardiovascular outcomes and mortality.Methods
In DEVOTE, patients with type 2 diabetes were randomised to receive either insulin degludec or insulin glargine U100 (100 units/ml) once daily (between dinner and bedtime) in an event-driven, double-blind, treat-to-target cardiovascular outcomes trial. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE; cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In the present analysis, the associations of severe hypoglycaemia with both MACE and all-cause mortality was evaluated in the pooled trial population using time-to-event analyses, with severe hypoglycaemia as a time-dependent variable and randomised treatment as a fixed factor. An investigation with interaction terms indicated that the effect of severe hypoglycaemia on the risk of MACE and all-cause mortality were the same for both treatment arms, and so the temporal association for severe hypoglycaemia with subsequent MACE and all-cause mortality is reported for the pooled population.Results
There was a non-significant difference in the risk of MACE for individuals who had vs those who had not experienced severe hypoglycaemia during the trial (HR 1.38, 95% CI 0.96, 1.96; p = 0.080) and therefore there was no temporal relationship between severe hypoglycaemia and MACE. There was a significantly higher risk of all-cause mortality for patients who had vs those who had not experienced severe hypoglycaemia during the trial (HR 2.51, 95% CI 1.79, 3.50; p < 0.001). There was a higher risk of all-cause mortality 15, 30, 60, 90, 180 and 365 days after experiencing severe hypoglycaemia compared with not experiencing severe hypoglycaemia in the same time interval. The association between severe hypoglycaemia and all-cause mortality was maintained after adjustment for the following baseline characteristics: age, sex, HbA1c, BMI, diabetes duration, insulin regimen, hepatic impairment, renal status and cardiovascular risk group.Conclusions/interpretation
The results from these analyses demonstrate an association between severe hypoglycaemia and all-cause mortality. Furthermore, they indicate that patients who experienced severe hypoglycaemia were particularly at greater risk of death in the short term after the hypoglycaemic episode. These findings indicate that severe hypoglycaemia is associated with higher subsequent mortality; however, they cannot answer the question as to whether severe hypoglycaemia serves as a risk marker for adverse outcomes or whether there is a direct causal effect.Trial registration
ClinicalTrials.gov NCT01959529Methods: Six children in Gross Motor Function Classification System classes I–III, aged 4–10 years, trained intensive active dorsiflexion in an interactive dynamic stander using ankle movement to play custom computer games following a 10-week control period. Gross Motor Function Measure Item Set, gait performance and passive and active dorsiflexion with extended and flexed knee were chosen as outcome parameters.
Results: Median active and passive ankle dorsiflexion increased significantly (5 and 10 degrees, respectively) with extended knee. There was a small but clinically significant increase in gross motor function. The intervention had no effect on temporospatial gait parameters.
Conclusion: In spite of the low number of participants, these results may indicate that intensive active stretching in an interactive dynamic stander could be an effective new conservative clinical treatment of ankle plantarflexor contracture in children with CP. 相似文献